Newsroom

Newsroom - 2025

Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie

Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya

Glenmark Pharmaceuticals Launches TEVIMBRA® in India

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies

Glenmark Pharma Reports Q4 & FY25 Financial results

Glenmark Foundation Leads Combat Against Malnutrition with its Transformative Initiative ‘Meri Poushtik Rasoi’ Season Seven

Glenmark Pharmaceuticals Inc., USA to launch Mixed Amphetamines Immediate-Release Tablets

Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)

Glenmark Nutrition Awards 2025: Celebrating Innovation, Impact, and Sustainability in the Fight Against Malnutrition in India

Glenmark Pharmaceuticals Inc., USA launches acquires and launches Acetylcysteine Injection 6 gm-30 mL (200 mg-mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial

Glenmark Pharma reports consolidated revenue growth of 35.1%, EBITDA margin of 17.7% and PAT margin of 10.3% YoY for Q3 FY2025

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution 0.005%

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules